Anika Therapeutics Completes First Human Surgical Procedure with Injectable HA-Based Bone Repair Therapy

- August 13th, 2019

Anika Therapeutics (NASDAQ:ANIK) has announced it has completed the first human surgical procedure with its injectable HA-based  bone repair therapy to treat bone voids and bone defects of the skeletal system. As quoted in the press release: The case was performed by Dr. John J. Tierney, an orthopedic surgeon at the New England Baptist Hospital … Continued

Anika Therapeutics (NASDAQ:ANIK) has announced it has completed the first human surgical procedure with its injectable HA-based  bone repair therapy to treat bone voids and bone defects of the skeletal system.

As quoted in the press release:

The case was performed by Dr. John J. Tierney, an orthopedic surgeon at the New England Baptist Hospital and President of the Greater Boston Orthopedic Center.

“My surgical experience with Anika’s product was very positive, and its ease of use surpassed that of other products I have used,” said Dr. Tierney. “My case went very smoothly, from start to finish, and I have every reason to believe that my patient will recover quickly post-operatively.”

Approximately 900,000 people require treatment for bone voids and other bone defects of the knee, which cause pain and impaired function that can lead to the need for total joint replacement therapy. This therapy combines calcium phosphate, an established precursor to the mineral component of bone, with Anika’s proprietary hyaluronic acid, which enhances flow and tactile feel during administration, to improve ease of use and procedural efficiency.

“Our injectable bone repair therapy is an innovative and easy-to-use treatment option, which is resorbed and replaced by the growth of new bone during the healing process,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “We are excited about this important milestone, and look forward to an initial commercial launch of the product under our hybrid commercial model in September, leveraging our specially-skilled regional sales directors to penetrate the market. We also plan to discuss the benefits of this novel therapy and value of our hybrid commercial strategy at our upcoming analyst and investor day.”

Click here to read the full press release.

Read our new 2019 medical device report today

 

 

Including: 3+ stocks to watch as well as valuable market data   Get My Free Report Click here to download for free

Leave a Reply

Your email address will not be published. Required fields are marked *